对于具有确定的分子亚型的骨髓母细胞瘤患者的治疗结果和预后因素
Xuejiao Shi1, Shuang Liu2, Xiaoyang Sun1
1Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Advances in radiation oncology
|August 21, 2025
概括
儿科骨髓母细胞瘤 (MB) 的治疗结果取决于分子亚型. 在放射治疗 (RT) 后获得完整的反应和接受适当的化疗对于更好的无事件生存 (EFS) 至关重要.
科学领域:
- 儿童瘤学
- 神经瘤学
- 分子诊断
背景情况:
- 骨髓母细胞瘤 (MB) 是一个异质的儿童脑瘤.
- 准确的风险分层对于定制治疗策略至关重要.
- 分子类型显著影响MB的预后和治疗反应.
研究的目的:
- 评估具有定义分子亚型的儿科骨髓母细胞瘤患者的治疗结果.
- 确定影响儿科MB治疗成功的预后因素.
- 根据分子和临床数据提供个性化治疗方法.
主要方法:
- 从2017年至2021年接受放射治疗的145名儿科MB患者的回顾性分析.
- 使用传统的临床,分子和国家综合癌症网络 (NCCN) 风险分层.
- 分析治疗结果,包括无事件生存率 (EFS) 和总生存率 (OS),以及相关预后因素.
主要成果:
- 五年EFS和OS率分别为68.6%和74.7%.
- 独立的不良预后因素包括不完整的治疗后反应,< 6 次化疗周期,以及高风险的NCCN分层.
- 分子标记如1q增加,10q损失,MYCN放大和TP53突变与EFS的恶化有关.
结论:
- 为了精确的风险分层,需要整合临床和分子特征.
- 治疗后的残留疾病,化学疗法不足和高风险的NCCN分层是独立的不良预后指标.
- 基于分子亚型的个性化治疗策略对于改善儿科MB结果至关重要.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K